Eli Lilly & Co. granted preliminary injunction against Teva
INDIANAPOLIS A U.S. District Court has granted drug maker Eli Lilly & Co. a preliminary injunction preventing the launch of a generic version of one of its drugs, Lilly announced Wednesday.
The company said the U.S. District Court for the Southern District of Indiana issued the injunction to prevent Teva Pharmaceuticals’ launch of raloxifene hydrochloride tablets, a generic version of Lilly’s osteoporosis drug Evista.
Patents on Evista begin expiring in 2012. The drug had sales of $700.5 million in 2008, according to Lilly financial data.
Roche says clinical trial did not meet goal
BASEL, Switzerland A biotech drug used to treat advanced cancer did not reduce the risk of cancer returning in patients with early-stage colon cancer when combined with chemotherapy, according to results of a late-stage clinical trial.
Roche said Wednesday that a phase 3 study comparing Avastin (bevacizumab) combined with chemotherapy to chemotherapy alone did not meet its goal of disease-free survival in colon cancer patients who had just received surgery.
The Swiss drug maker said the study, called NSABP C-08, was the first trial of Avastin as an early-stage cancer treatment. The drug, developed by recently acquired Genentech, already has approval in the United States for treating advanced colorectal, breast and lung cancers.
“While we are disappointed the C-08 study did not meet its primary endpoint, our initial review of the data leads us to continue to believe Avastin may be active in patients with early-stage colon cancer and look forward to NSABP’s presentation at ASCO,” Genentech SVP development and chief medical officer Hal Barron said, referring to the annual meeting of the American Society of Clinical Oncology, which will take place from May 29 to June 2.
NovaBay partners with medical professors to advance treatment development
EMERYVILLE, Calif. An American drug maker that develops drugs to treat and prevent infections has entered a partnership with professors from the Medical University of Innsbruck, Austria.
NovaBay Pharmaceuticals announced the partnership Wednesday with professors Waldemar Gottardi and Markus Nagl. NovaBay aims to advance development of its Aganocide compounds by integrating its development program with the university’s clinical work.
The Aganocide compounds are synthetic analogs of N-chlorotaurine, also known as NCT, an antimicrobial compound produced in the body’s white blood cells. Nagl and Gottardi have conducted extensive clinical research and produced patents and publications for several years on the use of the compound.
“We are very excited to collaborate with this world-class research team and pleased to draw on the extensive experience of professors Gottardi and Nagl in understanding the role of our class of molecules in the prevention and treatment of infectious diseases,” NovaBay chairman and CEO Ron Najafi said. “We look forward to building on their work to further expand the range of clinical opportunities provided by our Aganocide compound platform.”